608 related articles for article (PubMed ID: 32694315)
1. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
2. Ostectomy and Medial Plantar Artery Flap Reconstruction for Charcot Foot Ulceration Involving the Midfoot.
Sato T; Ichioka S
J Foot Ankle Surg; 2016; 55(3):628-32. PubMed ID: 26190780
[TBL] [Abstract][Full Text] [Related]
3. [Mid-Term Outcomes of Reconstruction of Charcot Foot Neuroarthropathy in Diabetic Patients].
Kučera T; Grinac M; Valtr O; Šponer P
Acta Chir Orthop Traumatol Cech; 2019; 86(1):51-57. PubMed ID: 30843514
[TBL] [Abstract][Full Text] [Related]
4. Surgical treatment of midfoot Charcot neuroarthropathy with osteomyelitis in patients with diabetes: a systematic review.
Ramanujam CL; Stuto AC; Zgonis T
J Wound Care; 2020 Jun; 29(Sup6):S19-S28. PubMed ID: 32530758
[TBL] [Abstract][Full Text] [Related]
5. Intramedullary foot fixation for midfoot Charcot neuroarthropathy.
Lamm BM; Siddiqui NA; Nair AK; LaPorta G
J Foot Ankle Surg; 2012; 51(4):531-6. PubMed ID: 22632840
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Diabetic Charcot Patients With and Without Foot Wounds.
Wukich DK; Sadoskas D; Vaudreuil NJ; Fourman M
Foot Ankle Int; 2017 Feb; 38(2):140-148. PubMed ID: 27923212
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.
Su HY; Yang CY; Ou HT; Chen SG; Chen JC; Ho HJ; Kuo S
JAMA Netw Open; 2023 Jan; 6(1):e2250639. PubMed ID: 36633847
[TBL] [Abstract][Full Text] [Related]
8. [Surgical treatment of the Charcot foot : long-term results and systematic review].
Hartig N; Krenn S; Trnka HJ
Orthopade; 2015 Jan; 44(1):14-24. PubMed ID: 25586504
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
10. Deformity and Clinical Outcomes Following Operative Correction of Charcot Foot: A New Classification With Implications for Treatment.
Pinzur MS; Schiff AP
Foot Ankle Int; 2018 Mar; 39(3):265-270. PubMed ID: 29172758
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors Associated With Major Lower Extremity Amputation After Osseous Diabetic Charcot Reconstruction.
Elmarsafi T; Anghel EL; Sinkin J; Cooper PS; Steinberg JS; Evans KK; Kim PJ; Attinger CE
J Foot Ankle Surg; 2019 Mar; 58(2):295-300. PubMed ID: 30850098
[TBL] [Abstract][Full Text] [Related]
12. Reverse Total Shoulder Arthroplasty Is the Most Cost-effective Treatment Strategy for Proximal Humerus Fractures in Older Adults: A Cost-utility Analysis.
Abdel Khalik H; Humphries B; Zoratti M; Axelrod D; Kruse C; Ristevski B; Rajaratnam K; Gardner M; Tarride JÉ; Johal H
Clin Orthop Relat Res; 2022 Oct; 480(10):2013-2026. PubMed ID: 35507306
[TBL] [Abstract][Full Text] [Related]
13. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
[TBL] [Abstract][Full Text] [Related]
14. Cost comparison: limb salvage versus amputation in diabetic patients with charcot foot.
Gil J; Schiff AP; Pinzur MS
Foot Ankle Int; 2013 Aug; 34(8):1097-9. PubMed ID: 23493775
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes and Complications of Midfoot Charcot Reconstruction With Intramedullary Beaming.
Ford SE; Cohen BE; Davis WH; Jones CP
Foot Ankle Int; 2019 Jan; 40(1):18-23. PubMed ID: 30284492
[TBL] [Abstract][Full Text] [Related]
16. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous surgical repair of a tibialis anterior tendon rupture and diabetic charcot neuroarthropathy of the midfoot: a case report.
Stapleton JJ
Clin Podiatr Med Surg; 2013 Oct; 30(4):599-604. PubMed ID: 24075138
[TBL] [Abstract][Full Text] [Related]
19. Preliminary Results of Primary Gastrocnemius-Soleus Recession for Midfoot Charcot Arthropathy.
Laborde JM; Philbin TM; Chandler PJ; Daigre J
Foot Ankle Spec; 2016 Apr; 9(2):140-4. PubMed ID: 26395022
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
